Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010053655 - THERAPEUTIC METHODS WITH WITHAFERIN A AND ANALOGS

Publication Number WO/2010/053655
Publication Date 14.05.2010
International Application No. PCT/US2009/060056
International Filing Date 08.10.2009
IPC
A61K 31/56 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC
A61K 31/56
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • UNIVERSITY OF KANSAS [US]/[US] (AllExceptUS)
  • COHEN, Mark, S. [US]/[US] (UsOnly)
  • SAMADI, Abbas [IR]/[US] (UsOnly)
  • TIMERMAN, Barbara, N. [US]/[US] (UsOnly)
Inventors
  • COHEN, Mark, S.
  • SAMADI, Abbas
  • TIMERMAN, Barbara, N.
Agents
  • REED, Carl, T.
Priority Data
61/112,46507.11.2008US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) THERAPEUTIC METHODS WITH WITHAFERIN A AND ANALOGS
(FR) PROCÉDÉS THÉRAPEUTIQUES UTILISANT LA WITHAFÉRINE A ET SES ANALOGUES
Abstract
(EN) Compounds of Formulas 1 (withaferin A, also referred to as D004), 2 (viscosalactone B, also referred to as E002), and 3 (22R-5β-formyl-6β,27-dihydroxyl-l -oxo-4-norwith-24- enolide, also referred to as O010), as well as salts, prodrugs, analogs, and derivatives thereof are biologically active for modulating Hsp70, Hsp90, and/or HSFl. Also, these compounds can be included in pharmaceutical compositions for administration to a subject for modulating the expression or activity of Hsp70, Hsp90, and/or HSFl in order to produce a therapeutic effect.
(FR) L'invention porte sur des composés représentés par les formules 1 (withaférine A, également appelée D004), 2 (viscosalactone B, également appelée E002), et 3 (22R-5β-formyl-6β,27-dihydroxyl-1-oxo-4-norwith-24-énolide, également appelé O010), ainsi que sur des sels, promédicaments, analogues et dérivés de ceux-ci qui sont biologiquement actifs pour moduler Hsp70, Hsp90, et/ou HSFl. Egalement, ces composés peuvent être compris dans des compositions pharmaceutiques pour une administration à un sujet pour la modulation de l'expression ou de l'activité de Hsp70, Hsp90, et/ou HSFl afin de produire un effet thérapeutique.
Latest bibliographic data on file with the International Bureau